Practical application of antidiabetic efficacy of lycium barbarum polysaccharide in patients with type 2 diabetes

Medicinal Chemistry

Volumn 11, Issue 4, 2015, Pages 383-390

  Caia, Huizhen ^a,b   Liu, Fukang ^a   Zuo, Pingguo ^a   Huang, Guiling ^a   Song, Zhixiu ^a   Wang, Tingting ^a   Luc, Huixia ^c   Guo, Fei ^c   Hand, Chao ^d   Sun, Guiju ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^d Shan Lijian Biological Technology Co   (China)

Author keywords

Cytokines.; Glucose; Lipids; Lycium barbarum polysaccharide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LYCIUM BARBARUM POLYSACCHARIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOCRINE PANCREAS FUNCTION TEST; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; INSULINOGENIC INDEX; LIPID BLOOD LEVEL; LIPID DIET; LYCIUM BARBARUM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL METABOLIC TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; AGED; AGONISTS; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LYCIUM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS, HDL; LYCIUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84989962402     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406410666141110153858     Document Type: Article

References (32)

1. Jin, M.L.; Huang, Q.S.; Zhao, K.; Shang, P. Biological activities and potential health benefit effects of polysaccharides isolated from Lycium barbarum L. Int. J. Biol. Macromol., 2013, 54, 16-23.
2. Zhu, J.; Liu, W.; Yu, J.P.; Zou, S.; Wang, J.J.; Yao, W.B.; Gao, X.D. Characterization and hypoglycemic effect of a polysaccharide extracted from the fruit of Lycium barbarum L. Carbohydr. Polym., 2013, 98(1), 8-16.
3. Amagase, H.; Farnsworth, N.R. A review of botanical characteristics, phytochemistry, clinical relevance in efficacy and safety of Lycium barbarum fruit (Goji). Food Res. Int., 2011, 44(7), 1702-17.
4. Zhao, R.; Li, Q.W.; Li, J.; Zhang, T. Protective effect of Lycium barbarum polysaccharide 4 on kidneys in streptozotocin-induced diabetic rats. Can. J. Physiol. Pharmacol., 2009, 87(9), 711-9.
5. Luo, Q.; Cai, Y.Z.; Yan, J.; Sun, M.; Corke, H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sci., 2004, 76(2), 137-49.
6. Li, W.; Wang, L.; Deng, X.; Jiang, L.; Zhang, C.; Zhang, C. Study of the fragility and abnormality rate of red blood cells in patients with type-2 diabetes and the effects of Lycium barbarum polysaccharides. Hebei J. Tradit. Chin. Med., 2000, 22(8), 585-6.
7. Wang, L.; Zhang, C.; Li, W. Regulating effect of Lycium barbarum Polysaccharide on T lymphocyte subpopulation and cytokines in patients with type-2 diabetes. Hebei J. Tradit. Chin. Med., 2001, 23(12), 888-890.
8. Weaver, R.R.; Lemonde, M.; Payman, N.; Goodman, W.M. Health capabilities and diabetes self-management: The impact of economic, social, and cultural resources. Soc. Sci. Med., 2014, 102, 58-68.
9. Danaei, G.; Finucane, M.M.; Lu, Y.; Singh, G.M.; Cowan, M.J.; Paciorek, C.J.; Lin, J.K.; Farzadfar, F.; Khang, Y.H.; Stevens, G.A.; Rao, M.; Ali, M.K.; Riley, L.M.; Robinson, C.A.; Ezzati, M. National, regional and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health ex-amination surveys and epidemiological studies with 370 countryyears and 2.7 million participants. Lancet, 2011, 378(9785), 31-40.
10. Global status report on noncommunicable diseases 2010. Geneva, World Health Organization, 2011.
11. Cai, H.Z.; Liu, F.K.; Lu, H.X.; Guo, F.; Hu, L.J.; Han, C.; Sun, G.J. Short-Term Intervention of Lycium barbarum Polysaccharide on Type 2 Diabetes. Food science (in Chinese), 2013, 33(13), 259-62.
12. Anderson, R.A.; Evans, M.L.; Ellis, G.R.; Graham, J.; Morris, K.; Jackson, S.K.; Lewis, M.J.; Rees, A.; Frenneaux, M.P. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis, 2001, 154(2), 475-83.
13. Tremblay, A.J.; Lamarche, B.; Deacon, C.F.; Weisnagel, S.J.; Couture, P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes. Metab., 2011, 13(4), 366-73.
14. Wray, W.; Boulikas, T.; Wray, V.P.; Hancock, R. Silver staining of proteins in polyacrylamide gels. Anal. Biochem., 1981, 118(1), 197-203.
15. Mcmanus, J.F.A. Histological demonstration of mucin after periodic acid. Nature, 1946, 158, 202.
16. Dubois, M.; Gilles, K.A.; Hamilton, J.K.; Rebers, P.A.; Smith, F. Colorimetric method for determination of sugars and related substances. Anal. Chem., 1956, 28(3), 350-6.
17. Chaplin, M.F. Monosaccharides; Oxford: Carbohydrate Analysis, 1986.
18. Noble, J.E.; Bailey, M.J.A. In: Quantitation of Protein. Methods Enzymol, 2rd ed; Academic Press: USA, 2009; Vol. 463, pp. 73-95.
19. Borm, G.F.; Hoogendoorn, E.H.; den Heijer, M.; Zielhuis, G.A. Sequential balancing: a simple method for treatment allocation in clinical trials. Contemp. Clin. Trials, 2005, 26(6), 637-45.
20. WHO. Guide to physical examination. who.int/chp/steps/manual/ en/index3.html
21. Ma, M.; Liu, G.H.; Yu, Z.H.; Chen, G.; Zhang, X. Effect of the Lycium barbarum polysaccharides administration on blood lipid metabolism and oxidative stress of mice fed high-fat diet in vivo. Food Chem., 2009, 113(4), 872-7.
22. Li, X.M. Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats. Int. J. Biol. Macromol., 2007, 40(5), 461-5.
23. D'Alessio, D.A.; Denney, A.M.; Hermiller, L.M.; Prigeon, R.L.; Martin, J.M.; Tharp, W. G.; Saylan, M.L.; He, Y.; Dunning, B.E.; Foley, J.E.; Pratley, R.E. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab., 2009, 94(1), 81-8.
24. Li, N.; Fu, J.F.; Koonen, D.P.; Kuivenhoven, J.A.; Snieder, H.; Hoflker, M.H. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? Atherosclerosis, 2014, 233(1), 130-8.
25. Preis, S.R.; Hwang, S.J.; Coady, S.; Pencina, M.J.; D'Agostino, R.B.; Savage, P.J.; Levy, D.; Fox, C.S. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 2009, 119, 1728-35.
26. Reiner, ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update Nutrition. Nutr. Metab. Cardiovas., 2013, 23(9), 799-807.
27. Catalamo, G.; Guerin, M. HDL and Reverse Cholesterol Transport: Physiological Modulation; The HDL Handbook: Biological Functions and Clinical Implications; Academic Press: USA, 2010.
28. Cheng, D.; Kong, H. The effect of Lycium barbarum polysaccharide on alcohol-induced oxidative stress in rats. Molecules, 2011, 16(3), 2542-50.
29. Mirza, S.; Hossain, M.; Mathews, C.; Martinez, P.; Pino, P.; Gay, J. L.; Rentfro, A.; McCormick, J. B.; Fisher-Hoch, S. P. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine, 2012, 57, 136-42.
30. Walsh, J.M.; McGowan, C.A.; Byrne, J.A.; Rath, A.; McAuliffe, F.M. The association between TNF-αnd insulin resistance in euglycemic women. Cytokine, 2013, 64(1), 208-12.
31. White, M.F. IRS-Protein Scaffolds and Insulin/IGF Action. Handbook of Cell Signaling; Academic Press: USA, 2003.
32. del Aguila, L.F.; Claffey, K.P.; Kirwan, J.P. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am. J. Physiol., 1999, 276, E849-55.